Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

Abstract

Spanish

French

BACKGROUND:

An up-to-date assessment of dipeptidyl peptidase-4 (DPP-4) inhibitors is needed to include newly available data.

OBJECTIVE:

To assess the efficacy and safety of DPP-4 inhibitors, including sitagliptin, saxagliptin, vildagliptin, and linagliptin, in type 2 diabetes.

METHODS:

We conducted a search of MEDLINE for randomized controlled trials (RCTs) of DPP-4 inhibitors in type 2 diabetes through November 2011, using the key terms sitagliptin, saxagliptin, vildagliptin, and linagliptin. We also searched for completed, but unpublished, trials at relevant web sites. RCTs were selected for meta-analysis if they (1) compared DPP-4 inhibitors with placebo or an antihyperglycemic agent; (2) had study duration of 12 or more weeks; (3) had 1 or more baseline and posttreatment efficacy and/or safety outcome; and (4) were published in English.

RESULTS:

In 62 evaluated articles, DPP-4 inhibitors lowered hemoglobin A_1c (A1C) significantly more than placebo (weighted mean difference [WMD] −0.76%; 95% CI −0.83 to −0.68); however, heterogeneity was substantial (I² = 82%). Exclusion of Japanese trials (n = 7) resulted in a reduction of heterogeneity (I² = 59%). In the non-Japanese RCTs (n = 55), DPP-4 inhibitors were associated with a reduction in A1C (WMD −0.65%; 95% CI −0.71 to −0.60) but higher risk of hypoglycemia (odds ratio [OR] 1.30; 95% CI 1.00 to 1.68) compared to placebo. The 7 Japanese-specific RCTs showed a greater reduction in A1C (WMD −1.67%; 95% CI −1.89 to −1.44) and a nonsignificant increase in risk of hypoglycemia (OR 1.41; 95% CI 0.51 to 3.88) with DPP-4 inhibitors versus placebo. When comparing DPP-4 inhibitors to active comparators, the I² was still high after deleting Japanese studies. In these 17 active comparator trials, there was no significant difference in A1C reduction (WMD 0.04%; 95% CI −0.09 to 0.16) or risk of hypoglycemia (OR 0.60; 95% CI 0.22 to 1.61) for DPP-4 inhibitors compared to other antihyperglycemics. There were similar odds of any or serious adverse events with DPP-4 inhibitors compared to placebo, but a decreased risk compared to other antihyperglycemics.

CONCLUSIONS:

DPP-4 inhibitors were associated with a reduction in A1C with comparable safety profiles compared to placebo, but no significant difference in A1C compared to other hyperglycemics. Differences in efficacy and safety were observed between Japanese and non-Japanese patients.

Keywords

dipeptidyl peptidase-4 inhibitors linagliptin meta-analysis saxagliptin sitagliptin vildagliptin

Get full access to this article

View all access options for this article.

References

Gupta

Walunj

Tokala

Parsa

Singh

Pal

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 2009;10:71–87.

Sitagliptin prescribing information. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf (accessed 2011 December 31).

Saxagliptin prescribing information. http://packageinserts.bms.com/pi/pi_onglyza.pdf (accessed 2011 December 31).

Linagliptin prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf (accessed 2011 December 31).

European Medicines Agency. European public assessment report: Galvus. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000771/WC500020328.pdf (accessed 2011 December 31).

Nathan

Buse

Davidson

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173–5.

Rodbard

Jellinger

Davidson

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009;15:540–59.

National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. http://www.nice.org.uk/CG87shortguideline (accessed 2011 May 1).

Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. http://www.fda.gov/newsevents/newsroom/pressannouncements/UCM226975.htm (accessed 2010 October 1).

10.

Neumann

Weill

Richordeau

Fagot

Alla

Allemand

Pioglitazone and risk of bladder cancer among patients in France: A population-based cohort study. Diabetologia 2012;55:1953–62.

11.

Amori

Lau

Pittas

. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007;298:194–206.

12.

Richter

Bandeira-Echtler

Bergerhoff

Lerch

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008;4:753–68.

13.

Monami

Iacomelli

Marchionni

Mannucci

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224–35.

14.

Fakhoury

Lereun

Wright

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44–57.

15.

Signirovitch

Swallow

Kantor

Fan

Gruenberger

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus. Clin Drug Investig 2011;31:665–74.

16.

Goldstein

Little

Lorenz

Malone

Nathan

Peterson

. Tests of glycemia in diabetes. Diabetes Care 2004;27(suppl 1):S91–3.

17.

Jadad

Moore

Carroll

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?

Control Clin Trials 1996;17:1–12.

18.

In: Effect sizes for dichotomous data. Fleiss

Berlin

. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation, 2009;237–53.

19.

Higgins

JPT

Thompson

. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.

20.

Sutton

Abrams

Jones

Sheldon

Song

Meta-analyses in medical research. Ontario, Canada: Wiley, 2000.

21.

Neumiller

Wood

Campbell

. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463–84.

22.

Macaskill

Walter

Irwig

A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001;20:641–54.

23.

Raz

Hanefeld

Caria

Williams-Herman

Khatami

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71.

24.

Aschner

Kipnes

Lunceford

Sanchez

Mickel

Williams-Herman

. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7.

25.

Hanefeld

Herman

Mickel

Sanchez

Stein

. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329–39.

26.

Mohan

Yang

Son

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106–16.

27.

Nonaka

Kakikawa

Sato

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291–8.

28.

Iwamoto

Taniguchi

Nonaka

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383–94.

29.

Goldstein

Feinglos

Lunceford

Johnson

Williams-Herman

. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979–87.

30.

Charbonnel

Karasik

Liu

Meininger

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–43.

31.

Raz

Chen

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537–50.

32.

Aaboe

Knop

Vilsboll

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:323–33.

33.

National Institutes of Health. A study to test the safety and efficacy of adding sitagliptin in patients with type 2 diabetes mellitus (MK0431–074). http://clinicaltrials.gov/ct2/show/NCT00813995 (accessed 2011 Nov 1).

34.

Rosenstock

Brazg

Andryuk

Stein

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–68.

35.

National Institutes of Health. A comparison of adding exenatide with switching to exenatide in patients with type 2 diabetes experiencing inadequate glycemic control with sitagliptin plus metformin. http://clinicaltrials.gov/ct2/show/NCT00870194 (accessed 2011 Nov 1).

36.

Hermansen

Kipnes

Luo

Fanurik

Khatami

Stein

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733–45.

37.

Vilsbøll

Rosenstock

Yki-Jarvinen

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167–77.

38.

Aschner

Katzeff

Guo

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252–61.

39.

Derosa

Maffioli

Salvadeo

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887–95.

40.

Bergenstal

Wysham

Macconell

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431–9.

41.

Scott

Sanchez

Stein

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171–80.

42.

Scott

Loeys

Davies

Engel

. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959–69.

43.

Nauck

Meininger

Sheng

Terranella

Stein

. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205.

44.

Ristic

Byiers

Foley

Holmes

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692–8.

45.

Dejager

Razac

Foley

Schweizer

Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218–23.

46.

Pi-Sunyer

Schweizer

Mills

Dejager

Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132–8.

47.

National Institute of Health. Vildagliptin 100 mg once daily vs. placebo as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. http://clinicaltrials.gov/ct2/show/study/NCT00494884 (accessed 2011 Nov 1).

48.

Kikuchi

Abe

Kato

Terao

Mimori

Tachibana

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83:233–40.

49.

National Institutes of Health. A study to compare the effect of vildagliptin compared to placebo in patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/study/NCT00351832 (accessed 2011 Nov 1).

50.

Bosi

Camisasca

Collober

Rochotte

Garber

. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890–5.

51.

Goodman

Thurston

Penman

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368–73.

52.

Garber

Schweizer

Baron

Rochotte

Dejager

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166–74.

53.

Garber

Foley

Banerji

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047–56.

54.

Fonseca

Schweizer

Albrecht

Baron

Chang

Dejager

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148–55.

55.

Kikuchi

Haneda

Koya

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;89:216–23.

56.

Bosi

Dotta

Jia

Goodman

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506–15.

57.

Schweizer

Couturier

Foley

Dejager

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955–61.

58.

Schweizer

Dejager

Bosi

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11:804–12.

59.

Pan

Yang

Barona

Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabet Med 2008;25:435–41.

60.

Ferrannini

Fonseca

Zinman

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157–66.

61.

Rosenstock

Kim

Baron

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175–85.

62.

Bolli

Dotta

Rochotte

Cohen

. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82–90.

63.

Rosenstock

Baron

Dejager

Mills

Schweizer

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–23.

64.

Blonde

Dagogo-Jack

Banerji

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: Results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11:978–86.

65.

Iwamoto

Kashiwagi

Yamada

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: A 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010;12:700–8.

66.

Rosenstock

Sankoh

List

. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376–86.

67.

Rosenstock

Aguilar-Salinas

Klein

Nepal

List

Chen

Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401–11.

68.

Pan

Yang

Tou

Gause-Nilsson

Zhao

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Metab Res Rev 2012;28:268–75.

69.

National Institutes of Health. Evaluate saxagliptin in adult Indian patients with type 2 diabetes inadequate glycemic control. http://clinicaltrials.gov/ct2/show/NCT00918879 (accessed 2011 Nov 1).

70.

National Institutes of Health. Study of BMS-477118 as monotherapy with titration in subjects with type 2 diabetes who are not controlled with diet and exercise. http://clinicaltrials.gov/ct2/show/NCT00316082 (accessed 2011 Nov 1).

71.

DeFronzo

Hissa

Garber

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649–55.

72.

Yang

Pan

Tou

Zhao

Gause-Nilsson

Efficacy and safety of saxagliptin added to metformin in Asian patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Res Clin Pract 2011;49:217–24.

73.

National Institutes of Health. Efficacy and safety study of subjects that are taking saxagliptin added onto metformin immediate release (IR), twice daily, compared to subjects taking metformin IR alone. http://clinicaltrials.gov/ct2/show/NCT00885378 (accessed 2011 Nov 1).

74.

Hollander

Allen

Chen

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810–9.

75.

Chacra

Tan

Apanovitch

Ravichandran

List

Chen

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract 2009;63:1395–406.

76.

Jadzinsky

Pfutzner

Paz-Pacheco

Allen

Chen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009;11:611–22.

77.

Del Prato

Barnett

Huisman

Neubacher

Woerle

Dugi

. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2011;13:258–67.

78.

National Institutes of Health. Randomized, double-blind (db), placebo-controlled 18 week study of linagliptin (BI 1356) in type 2 diabetic patients with insufficient glycaemic control on a sulfonylurea drug. http://clinicaltrials.gov/ct2/show/NCT00819091 (accessed 2011 Nov 1).

79.

National Institutes of Health. Efficacy and safety of 3 doses of BI1356 (linagliptin) in type 2 diabetes patients. http://clinicaltrials.gov/ct2/show/NCT00328172 (accessed 2011 Nov 1).

80.

Forst

Uhlig-Laske

Ring

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010;27:1409–19.

81.

Taskinen

Rosenstock

Tamminen

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65–74.

82.

Gomis

Espadero

Jones

Woerle

Dugi

. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653–61.

83.

Owens

Swallow

Dugi

Woerle

. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study. Diabet Med 2011;28:1352–61.

84.

Kawamori

Inagaki

Araki

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: A randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14:348–57.

85.

Baetta

Corsini

Pharmacology of dipeptidyl peptidase-4 inhibitors. Drugs 2011;71:1441–67.

86.

American Diabetes Association. Standard of medical care in diabetes-2010. Diabetes Care 2010;33(suppl 1):S11–61.

87.

Esposito

Cozzolino

Bellastella

Maiorino

. Dipeptydil peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13:594–603.